Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with EGFR-mutated NSCLC and Leptomeningeal Metastases
Findings from the BLOSSOM study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma
Evidence for efficacy is based on the results from the KEYNOTE-868/NRG-GY018 study
A Favourable Benefit-Risk Profile for Taletrectinib in TKI-Naїve and Crizotinib-Pretreated Patients with ROS1-positive NSCLC
Findings from the TRUST-I study
After 5 Years of Follow-Up, the Median PFS Has Yet To Be Reached in Patients with ALK-positive Advanced NSCLC Treated with First-Line Lorlatinib
Findings from the CROWN study
Adding Olanzapine to Standard Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting
Findings from a phase III study
Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy
Second tumour is rare and may occur through various mechanisms in susceptible patients
EMA Recommends Granting a Conditional Marketing Authorisation for Odronextamab
It is intended for the treatment of adult patients with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma
Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive Advanced/Metastatic NSCLC
Findings from the BFAST study support the clinical applicability of liquid biopsies
FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer
Evidence for efficacy is based on the results of the DUO-E study
One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among Patients with Stage I HER2-positive Breast Cancer
HER2DX score was significantly associated with the risk of recurrence in the ATEMPT study
EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with Endometrial Cancer
New indication concerns a combination with durvalumab for the maintenance treatment of mismatch repair proficient primary advanced or recurrent endometrial cancer
PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients with Newly Diagnosed, Advanced-Stage cHL
Findings from the HD21 study